Autism is complex. No one has yet presented a comprehensive understanding of the disease process. In this article, I wanted to touch upon some simple core principles. I hope that by the end of it you start to see that what is happening here is beyond concerning.
According to the CDC, laboratory testing newly diagnosed individuals with autism is not recommended. This means no celiac antibodies, allergy testing, immunologic or neurochemical abnormalities, micronutrients such as vitamin levels, intestinal permeability studies, stool analysis, urinary peptides, mitochondrial disorders, thyroid function tests, or erythrocyte glutathione peroxidase studies. And these are just basic tests. We are not even talking about more complex lab tests like nagalase and glyphosate. So don’t be surprised if your pediatrician thinks you are a little kooky!
Here, I will make a blunt claim about a very toxic chemical: Glyphosate. The effects of glyphosate on the human organism are horrendous. I will present scientific evidence of harm. The effects of this herbicide on the brain will explain why autism can present as such an acute regression. I specifically wanted to highlight a key finding I came across, which hopefully will be an eye-opener for those who are starting to grasp the magnitude of this.
In part two: “The Role of Phytocannabinoids in Autism Therapy“, we provided a brief overview of the preclinical research implicating the role that the endocannabinoid system (ECS) plays in the progression of autism spectrum disorder (ASD), preclinical research supporting targeting the ECS to treat ASD, and provided a number of preclinical studies indicating the potential value of phytocannabinoids in treating symptoms and diseases associated with ASD.
Here we’ll examine the shortcomings of current research, explore possible adverse effects of cannabinoid treatments, discuss the types of autism that may currently warrant cannabinoid treatments, and illustrate how a family might systematically approach a cannabinoid treatment for ASD. … Continue Reading
In part one of this series the preclinical scientific evidence illustrating the involvement of the endocannabinoid system (ECS) in the physiological progression of Autism Spectrum Disorder (ASD) and comorbid conditions was provided. Here we’ll highlight some of the pharmacological characteristics that phytocannabinoids share with endocannabinoids, the use of phytocannabinoids in the treatment of symptoms and diseases associated with ASD, and why having access to a variety of cannabis chemotypes will always be preferable to a select cannabinoid and/or ratio. … Continue Reading